1	Reverse Transcription-Loop-Mediated Isothermal Amplification (RT-LAMP) is
2	an effective alternative for SARS-CoV-2 molecular detection in middle-income
3	countries
4	Oscar Escalante-Maldonado ¹ , Margot Vidal-Anzardo ^{1,4} , Fernando Donaires ¹ , Gilmer
5	Solis-Sanchez ¹ , Italo Gallesi ¹ , Luis Pampa-Espinoza ¹ , Maribel Huaringa ¹ , Nancy
6	Rojas Serrano ¹ , Coralith García ² , Eddie Angles-Yanqui ^{3,4} , Ronnie Gustavo Gavilán ¹ ,
7	Ricardo Durães-Carvalho ⁶ , Cesar Cabezas ¹ , Paulo Vitor Marques Simas ^{1,5,6}
8	
9	1. Instituto Nacional de Salud, Lima, Peru
10	2. Hospital Nacional Cayetano Heredia, Lima, Peru
11	3. Hospital Nacional Arzobispo Loayza, Lima, Peru
12	4. Universidad Peruana Cayetano Heredia, Lima, Peru
13	5. Universidad Nacional Mayor de San Marcos, Lima, Peru
14	6. University of Campinas, Institute of Biology, Laboratory of Animal Virology,
15	Campinas, SP, Brazil
16	
17	Corresponding author:
18	Oscar Escalante-Maldonado, PhD
19	Nacional Institute of Health, Ministerio de Salud, Jirón Capac Yupanqui 1400, Jesús
20	María 15072, Lima, Peru.
21	Phone: +51 (511) 748-1111 Extension line 2136
22	E-mail: <u>oescalante@ins.gob.pe; oscar.escmal@gmail.com</u>

2	2
Z	3

ABSTRACT

24 Molecular diagnosis of SARS-CoV-2 in developing countries is still a big challenge. 25 The reference standard, RT-qPCR, recommended by WHO, is not widely available, difficulting early identification of cases. Furthermore, the transport logistic between 26 the sample collection point and the laboratory facilities can alter the samples, 27 28 producing false negative results. RT-LAMP is a cheaper, simpler molecular technique 29 that can be an interesting alternative to be offered in hospital laboratories. We present the evaluation of a RT-LAMP for diagnosis of SARS-CoV-2 in two steps: the 30 31 laboratory standardization and the clinical validation, comparing it with the standard 32 RT-qPCR. In the standardization phase, limit of detection and robustness values 33 were obtained using RNA from a Peruvian SARS-CoV-2 strain. It presented 100% 34 agreement between triplicates (RT-LAMP agreement with all RT-gPCR reactions that 35 presented Ct \leq 30) and robustness (RT-LAMP successful reactions with 80%) 36 reaction volume and 50% primer concentration). 384 nasal and pharyngeal swabs collected from symptomatic patients and stored in the INS biobank were tested and 37 we obtained 98.75%, 87.41%, 97.65% and 92.96% for specificity, sensitivity, positive 38 predictive value and negative predictive values respectively. Then, 383 samples from 39 40 symptomatic patients with less than 15 days of disease, were tested both with the RT-LAMP and with the RT-gPCR, obtaining e 98.8%, 88.1%, 97.7% y 93.3% of 41 specificity, sensitivity, positive predictive value and negative predictive values 42 43 respectively. The laboratory standardization and the clinical validation presented the 44 same value by Kappa-Cohen index (0.88) indicating an almost perfect agreement 45 between RT-LAMP and RT-qPCR for molecular detection of SARS-CoV-2. We 46 conclude that this RT-LAMP protocol presented high diagnostic performance values 47 and can be an effective alternative for COVID-19 molecular diagnosis in hospitals,

- 48 contributing to early diagnosis and reducing the spread of virus transmission in the
- 49 Peruvian population.
- 50
- 51 **KEYWORDS:** COVID-19; molecular testing; RT-LAMP; healthcare unit.

52 **1. INTRODUCTION**

The World Health Organization (WHO) declared COVID-19 as a pandemic in the beginning of March. Since, the virus has been detected in every continent and produced more than 1 million deaths. Currently, some Latin America countries such as Brazil and Peru are considered pandemic epicenters [1], but many more low and middle –income countries are facing important health constraints.

Molecular tests require considerable financial and logistical investments, when compared to other diagnostic tools. The reference standard test suggested by WHO, the Real Time Reverse Transcription Polymerase Chain Reaction (RT-qPCR), requires molecular laboratory facilities, uses expensive equipment (thermocycler), reagents (probes) and specialized staff all of which are not always widely available in these countries. Results are available between 4 and 8 hours of processing [2, 3].

In Peru, at the beginning of the pandemic, RT-qPCR was only able to be performed in a standardized way in Lima (capital of the country) in the National Reference Laboratory of Respiratory Viruses of the Instituto Nacional de Salud (INS).

Progressively, the diagnosis was extended to regional laboratories in a decentralized manner, but the demand for these tests, in practice, has not been fully met in some places. This situation has led to the concern of the local scientific community for the development of diagnostic alternatives.

On the other hand, the simple and low-cost reverse transcription loop-mediated isothermal amplification (RT-LAMP) method could be a good alternative for molecular diagnosis in places where there is no complete laboratory infrastructure, particularly in hospitals. It is an isothermal technique that uses from four to six primers, two/three forward and two/three reverse to identify DNA targets to allow its amplifications. RT-LAMP uses cheaper equipment, is fast (results generally available in almost 50

minutes, without considering sampling and RNA extraction time) and highly sensible
[4]. There are several publications about this technique, showing good results when
compared to the RT-qPCR method.

Our goal was to develop a RT-LAMP for molecular detection of SARS-CoV-2 and to evaluate its diagnostic performance both through basic laboratory standardization as well as through assessment of diagnostic parameters in patients with clinical suspicion of COVID-19, comparing it with RT-qPCR as the reference standard.

85

86 2. MATERIAL AND METHODS

87 2.1. ETHICAL CONSIDERATIONS

The laboratory standardization did not need to be sent for evaluation by the Ethics Committee since it is included in the action plan of INS-Peru. Nonetheless, all samples were processed completely anonymously. The clinical validation protocol was submitted to the Ethics Committee of the INS-Peru and approved on August 6th, 2020, under the procedure "Revisión de protocolos en el marco de epidemias, brotes o situaciones de emergencia" as indicates RD No. 283-2020-OGITT-INS.

94

95 2.2. EXPERIMENTAL DESIGN

The diagnostic performance values of RT-LAMP in comparison to RT-qPCR were obtained from qualitative and quantitative parameters used for laboratory standardization and clinical assessment. All experiments were conducted under the same conditions (samples, equipment, technicians and environment).

100

101 **2.3. SAMPLES AND EVALUATION PARAMETERS**

102 2.3.1. LABORATORY STANDARDIZATION

The limit of detection and the robustness (concordance degree of the results 103 when we change primers concentration - 0.5P - and the final volume of reaction-104 0.8V, 0.6V, 0.5V and 0.4V) were performed using a SARS-CoV-2 Peruvian strain 105 isolated and titred in Vero cell line. The cross-reaction analysis was performed in 106 107 silico using multiple sequences alignment between external primers of RT-LAMP and 108 reference sequences for all known human coronaviruses (HCoV) (NC 005831.2, HCoV-NL63; NC 002645.1, HCoV-229E; NC 006213.1, HCoV-OC43 strain ATCC 109 VR-759; NC 006577.2, HCoV-HKU1; NC 004718.3, Severe Acute Respiratory 110 111 Syndrome-related Coronavirus Type 1; NC_019843.3, Middle East Respiratory 112 Syndrome-related Coronavirus: FJ415324.1, HECoV 4408) and SARS-CoV-2 strains from strains from China (NC 045512.2) and Peru (all complete sequences made 113 available on the GISAID) [5]. 114

115 Specificity, sensitivity positive and negative predictive values were obtained 116 through evaluation of 384 nasal and pharyngeal swabs collected from routine 117 epidemiological screening. From these, 193 were submitted to a new RT-LAMP 118 round by other laboratory technician and equipment to test the reproducibility. The 119 sample size was calculated using the formula for difference between 2 proportions 120 assuming a 90% power and a 95% confidence interval [6] from the total number of 121 samples processed by RT-qPCR (almost 240,000 samples until July 2020).

122

123 **2.3.2. CLINICAL ASSESSMENT**

124 Specificity, sensitivity, positive and negative predictive values were 125 obtained through evaluation of 383 COVID-19 suspected people up to 15 days after 126 symptom onset, from Lima, Peru, assessed in Hospital Cayetano Heredia, Hospital

Hipolito Unanue and Hospital Arzobispo Loayza and patients that were treated by 127 home care teams. The sample size was calculated using Epidat software version 128 4.2, considering an estimate of 91.489% sensitivity and 99.531% specificity 129 according to Jiang et al. [7]. People older than 18 years old without a previous 130 diagnosis of COVID-19 by molecular test were included in the study after signature 131 132 of informed consent. Pregnant women and severe or critical patients were excluded. 133 The validation criteria considered 95% significance level, 5% absolute error and 39.5% positivity probability (based in the positive results obtained by RT-gPCR 134 reported by INS-Peru and assuming a loss rate of 20%). Nasal and pharyngeal 135 136 swabs were performed on each subject, using the Yocon Biology Technology 137 Company sampling kit, which includes viral transport media and flocked dacron swabs. The samples were transported to the INS-Peru using triple containers with 138 cold accumulators, at temperatures between 2 to 8 ° C. 139

140

141 **2.4. MOLECULAR DETECTION OF SARS-CoV-2**

142 **2.4.1. RNA EXTRACTION**

The RNA extraction was performed using GenElute[™] Total RNA
Purification Kit (Sigma-Aldrich – Merck), according to manufacturers' instructions,
then quantified by NanoDrop[™] Spectrophotometer and frozen to -80°C until further
processing.

147

148 **2.4.2. RT-qPCR REACTION**

The primers and probes used in the RT-qPCR reactions standardized by INS-PERU, is available in table 1. The RT-qPCR was performed using Rotor-Gene Multiplex RT-PCR Kit, according to the RT-qPCR standardized and implemented to

- 152 COVID-19 diagnosis at the INS-Peru, summarized in the tables 2 (reactions
- 153 conditions) and 3 (amplification conditions).

154

Table 1: Target genes, oligonucleotides and probes used in the RT-qPCR reactions. The targets for amplification were RNA dependent RNA polymerase (*RdRp*) specific for SARS-CoV-2 and the Glyceraldehyde-3-Phosphate Dehydrogenase (*GAPDH*), a human constitutive gene. The sample quality, the RNA extraction and amplifications performances were evaluated in a single multiplex reaction using GAPDH as internal control.

	TARGET	PRIMER / PROBE	SEQUENCE 5' \rightarrow 3'
		RdRp_SARSr-F	GTGARATGGTCATGTGTGGCGG
	RdRp	RdRp_SARSr-P2	FAM-CAGGTGGAACCTCATCAGGAGATGC-BBQ
		RdRp_SARSr-R	CARATGTTAAASACACTATTAGCATA
		GAPDH-F	GTGAAGGTCGGAGTCAACGG
	GAPDH	GAPDH-P	ROX-CGCCTGGTCAACAGGGTCGC-BBQ
		GAPDH-R	TCAATGAAGGGGTCATTGATG

161

162 **Table 2**: Conditions of RT-qPCR multiplex reactions for SARS-CoV-2 and GAPDH

using Capital[™] RT-qPCR Probe Mix 4X (Biotechrabbit).

REAGENTS and CONCENTRATIONS	VOLUME (µL)
RdRp_SARSr-F (10 μM)	0.8
RdRp_SARSr-P2 (10 μM)	0.8
RdRp_SARSr-R (10 μM)	0.4
GAPDH-F (2.5 μM)	0.5
GAPDH-Ρ (2.5 μM)	0.5
GAPDH-R (1.25 μΜ)	0.4
RTase with RNAse inhibitor	1.0
qPCR PROBE MIX	5.0
Nuclease Free Water	5.6
FINAL VOLUME	15.0

164

Table 3: Conditions of RT-qPCR multiplex amplification for SARS-CoV-2 and GAPDH using CapitalTM RT-qPCR Probe Mix 4X (Biotechrabbit).

STEPS	TEMPERATURE	TIME	NUMBER of CYCLES
Reverse	50°C	10 minutes	1

Transcription			
Initial denaturation	95 °C	3 minutes	1
qPCR amplification	95 °C 58 °C 40 °C	10 seconds 30 seconds 30 seconds	45

167

168 2.4.3. RT-LAMP REACTION

The RT-LAMP reactions were performed according to Lamb et al. (2020) [8] using WarmStart Colorimetric LAMP 2X Master Mix, containing a pH indicator which allows the colorimetric visualization. The robustness was tested from standard primers concentration and final volume of reaction. The concentrations of reagents and the reactions conditions were summarized in table 4.

Table 4: Conditions of RT-LAMP reactions to detect SARS-CoV-2, according to Lamb et al. (2020). The primers' names were the same on the original publication.

PRIMERS (100 µM)	Volume (µl)	REAGENTS	Volume (µL)	
FIP	16.0	MIX-LAMP	12.5	
BIP	16.0	MIX-Primers	2.5	
F3	2.0	Water	5.0	
B3	2.0	RNA	5.0	
LOOP F	4.0	Final Volume	25.0	
BUCLE B	4.0	THERMAL CONDITIONS		
Water	56.0	45 minutes at 65°C		
Final Volume	100.0	5 minutes at 80°C		

176

177 2.5. STATISTICAL ANALYSIS

Data analysis was performed using the Stata v16.1 statistical package (Stata Corporation, College Station, Texas, USA); point estimators and 95% confidence intervals of the clinical-epidemiological characteristics of the people evaluated were calculated. The values of the diagnostic performance measures of RT-LAMP in comparison with RT-qPCR were calculated; considering: sensitivity, specificity,

positive and negative predictive value, positive and negative likelihood ratio, area under the ROC curve, Matthews Correlation Coefficient and F1-Score. The degree of concordance between the results of both tests was determined, as well as the agreement using Cohen's Kappa index. These analyzes were carried out for all evaluated cases, as well as in a stratified way according to week of illness. The relationship between time of symptoms and Ct values was established using Pearson's correlation coefficient.

190

191 **3. RESULTS**

192 3.1. LABORATORY STANDARDIZATION

The limit of detection for SARS-CoV-2 by RT-LAMP was consistent only with those with Ct values < 30 in the RT-qPCR reactions (standard curve presented into figure 1, panel A, and RT-LAMP performance reaction, panel B) and RT-LAMP in table 5. This means that the RT-LAMP test was efficient to detect up to 1000 copies/ μ L of the target gene. In the robustness experiments, high reactions performances were obtained with half of primers concentrations (0.5P) and with 20 μ L of final volume (0.8V from final volume of standard reaction).

200

Table 5: Comparison of limit of detection between RT-qPCR and RT-LAMP reactions
 to detect SARS-CoV-2.

203

SERIAL DILUTION CONCENTRATION	10 ⁻¹ 10 ⁷	10 ⁻² 10 ⁶	10 ⁻³ 10 ⁵	10 ⁻⁴ 10 ⁴	10 ⁻⁵ 10 ³	10 ⁻⁶ 10 ²	10 ⁻⁷ 10 ¹
(number of copies/µL) Ct VALUES (RT-qPCR)	13.59	16.70	20.37	25.04	29.17	35.12	-
COLOR CHANGE (RT-LAMP)	Yes	Yes	Yes	Yes	Yes	No	No

204

Figure 1: Standard curve of RT-qPCR (panel A) reactions and limit of detection by RT-LAMP (panel B) in two molecular methods to detect SARS-CoV-2.

The "cross-reaction analysis" performed in silico identified a very low-208 209 similarity degrees between the primers alignment and reference sequences of HCoV 210 NL-63, HKU1, OC43, 229E, SARS-CoV-1, MERS and HECoV (figure 2: panel A 211 refers to F3 primer alignment – forward; panel B refers to B3 primer alignment – reverse). These data, would indicate the absence of amplification of other HCoV, if 212 they to be present in the sample. The yellow columns correspond to conserved 213 214 regions. In addition, when these same primers were aligned with 194 Peruvian strains made available on GISAID initiative, there was none exclusion of conserved 215 216 regions, exhibiting a high-similarity and specificity, which may be designated as 217 absence of concomitant detection of other HCoV non-SARS-CoV-2.

218

Figure 2: Multiple sequence alignment between RT-LAMP external primers 219 F3 and B3 (Lamb et al., 2020) and reference sequences of all known human 220 coronaviruses and all SARS-CoV-2 Peruvian strains made available on GISAID 221 initiative. The alignment was conducted in ClustalW using MEGA. The primers 222 223 sequences (panel A - F3, panel B - B3) were aligned with all reference sequences of known HCoV (NC 005831.2, HCoV-NL63; NC 002645.1, HCoV-229E; 224 225 NC_006213.1, HCoV-OC43 strain ATCC VR-759; NC 006577.2, HCoV-HKU1; 226 NC_004718.3, SARS-CoV-1; NC_019843.3, MERS; FJ415324.1, HECoV-4408 and 227 NC 045512.2, SARS-CoV-2 isolate Wuhan-Hu-1) and all 194 SARS-CoV-2 Peruvian 228 strains (panel C - F3, panel D - B3). The yellow columns, on the panels A and B, and asterisks, on the panels C and D, represent conserved regions into nsp3 gene 229 fragment between the all known HCoV and all SARS-CoV-2 Peruvian strains 230 complete genome, respectively. 231

232 233

The positivity obtained for each method, RT-qPCR and RT-LAMP, is presented in table 6. The values of Cohen's kappa index comparing the diagnostic performance between both methods indicated a nearly perfect agreement between

them, with the best agreement on the onset of symptoms.

Table 6: Results obtained in the laboratory standardization for performance
 diagnostic comparison between RT-LAMP and RT-qPCR in the SARS-CoV-2
 molecular detection.

	RT-o	qPCR	Kappa Index
	Positive	Negative	(IC 95%)
Positive	125 (TP*)	3 (FP [†])	0.99
Negative	18 (FN ^{††})	238 (TN**)	0.00

TP*: True positive; TN**: True negative; FP^T: False Positive; FN^{TT}: False Negative (According to Parik et al., 2008) [9]

243

244 3.2. CLINICAL ASSESSMENT

The study population was composed by 51.7% (n = 198) women and 48.3% (n = 185) men, being young adults the most frequent age group (n = 236, 61.6%). The most common symptoms were cough (n = 268, 70.0%) and pharyngeal pain (n = 262, 68.4%). Regarding time of symptom onset, the average was 7.1 \pm 3.3 days, and 56.3% belong to the first week after symptom onset patients (group 1) and 43.7% belong to the second week after symptom onset patients (group 2). One case was excluded due to memory bias.

We determined 37.3% positive samples by RT-qPCR and 33.7% by RT-252 LAMP (table 6). Among the 143 positive results by RT-qPCR, only 20 clinical 253 samples had discordant results with RT-LAMP, 17 were false negatives and 3 were 254 false positives. In group 1, the Ct was between 31.00 and 36.46, with a median of 255 34.43 (IQR: 34.2, 35.56). In group 2, the Ct values were higher than 37. The true 256 positive data presented significant concordance (p < 0.001) between both tests 257 (Kappa index: 88.6; 95% CI between 83.8 and 93.5); being in group 1, 70 of 76 258 259 positive cases (Kappa index: 91.8; 95% CI between 86.2 and 97.4), while in group 2, 260 56 of 67 cases (Kappa index: 84.7; 95% CI between 76.4 and 93.0]) (table 7).

261

Table 6: Clinical and epidemiological data related to the study population (gender, age grouping, signs and symptoms, time of illness onset, positivity by RT-qPCR and by RT-LAMP.

n	%	95% CI

Gender			
Male	185	48.3	43.2; 53.4
Female	198	51.7	46.6; 56.8
Age Grouping			
Young	62	16.2	12.6; 20.3
Young Adult	236	61.6	56.5; 66.5
Elderly	85	22.2	18.1; 26.7
Signs and symptoms			
Ageusia (loss or impairment of the sense of	19	5.0	3.0; 7.6
taste)			
Anosmia	37	9.7	6.9; 13.1
Headache	214	55.9	50.7; 60.9
Nasal congestion	127	33.2	28.5; 38.1
Diarrhea	80	20.9	16.9; 25.3
Dyspnea	90	23.5	19.3; 28.1
Joint pain	27	7.0	4.7; 10.1
Sore throat	262	68.4	63.5; 73.0
Muscle pain	113	29.5	25.0; 34.3
Chest pain	67	17.5	13.8; 21.7
Fever or chill	179	46.7	41.7; 51.9
Irritability or Confusion	2	0.5	0.1; 1.9
General discomfort	232	60.6	55.5; 65.5
Nausea or Vomiting	46	12.0	8.9; 15.7
Cough	268	70.0	65.1; 74.5
Time of symptom Onset *			
First week	215	56.3	51.1; 61.3
Second week	167	43.7	38.7; 48.9
Positivity by RT-qPCR			
Negative	240	62.7	57.6; 67.5
Positive	143	37.3	32.5; 42.4
Positivity by RT-LAMP			
Negative	254	66.3	61.3; 71.0
Positive	129	33.7	29.0; 38.7

²⁶⁵ *Data obtained from 382 patients (one patient was excluded due memory bias).

Table 7: Results from clinical validation, comparing diagnostic performance between
 RT-LAMP and RT-qPCR for SARS-CoV-2 molecular detection. This data was used to
 calculate the sensitivity, specificity, predictive positive (PPV) and predictive negative
 (PNV) values.

	RT-qPCR		Kappa Index	Concordance	n valua			
	Positive	Negative	(IC 95%)	%	p-value			
Overall								
Positive	126 (TP*)	3 (FP [†])	0 00 (0 02. 0 02)	04.9	-0.001			
Negative	17 (FN ^{††})	237 (TN**)	0.00 (0.03, 0.93)	34.0	<0.001			

²⁶⁶

	RT-q	PCR	Kappa Index	Concordance	n_value
	Positive	Negative	(IC 95%)	%	p-value
		First wee	k of symptoms		
Positive	70 (TP*)	$2 (FP^{\dagger})$	0.01 (0.96: 0.07)	06.2	-0.001
Negative	6 (FN ^{††})	137 (TN**)	0.91 (0.66, 0.97)	90.3	<0.001
		Second we	ek of symptoms		
Positive	56 (TP*)	1 (FP^{\dagger})	0.94 (0.76: 0.02)	02.0	-0.001
Negative	11 (FN ^{††})	99 (TN**)	0.64 (0.76, 0.95)	92.0	<0.001

TP*: True positive; TN**: True negative; FP[†]: False Positive; FN^{††}: False Negative (According to Parik et al., 2008) [9].

3.3. DIAGNOSTIC PERFORMANCE of RT-LAMP

The sensitivity was 88.1% (95% CI: 81.6; 92.9) and the specificity, 98.8% (95% CI: 96.4; 99.7). These values presented variations when a stratified evaluation was made by time of symptom onset; where the sensitivity reaches 92.1% in the first week, while for the second it drops to 86.6%. However, the specificity showed minimal variation, with 98.6% and 99.0% for the first and second week respectively (table 8).

The positive predictive value was 97.7%, which showed an increase according to the time of symptom onset, from 97.2%, in the first week, to 98.2%, for the second. It was identified that the overall positive likelihood ratio of the test was 70.5, taking values of 64.0 and 83.6 in the first and second week respectively. Meanwhile, the negative likelihood ratio was 0.12, with values of 0.08 in the first week, and 0.17 for the second. The accuracy tends to show lower results as the time of illness onset progresses.

	LAB	ORATORY	CLINICAL ASSESSMENT										
PARAMETERS	STAND	ARDIZATION	C	Overall	Firs sy	t week of mptoms	Seco sy	nd week of mptoms					
	%	95% CI	%	95% CI	%	95% CI	%	95% CI					
Sensitivity*	87.4	80.8; 92.4	88.1	81.6; 92.9	92.1	83.6; 97.0	86.6	72.5; 91.5					
Specificity**	98.8	96.4; 99.7	98.8	96.4; 99.7	98.6	94.9; 99.8	99.0	94.6; 100					
Positive Predictive Value†	97.7	93.3; 99.5	97.7	93.4; 99.5	97.2	90.3; 99.7	98.2	90.6; 100					
Negative Predictive Value‡	93.0	89.1; 95.8	93.3	89.5; 96.1	95.8	91.0; 98.4	90.0	82.8; 94.9					
Accuracy	94.5	91.8; 96.6	94.8	92.1; 96.8	96.3	92.8; 98.4	92.8	87.8; 96.2					
Area Under curve	93.1	90.3; 95.9	93.4	90.7; 96.2	95.3	92.1; 98.5	91.3	86.7; 95.9					
Matthews Correlation Coefficient	88.4		88.9		91.8		85.4						
F1 Score	92.3		92.6		94.6		90.3						

*Sensitivity [(TP)/(TP+FN)]; **Specificity [(TN)/(TN+FP)]; †PPV [(TP)/(TP+FP)]; ‡NPV [(TN)/(TN+FN)] (According to Parik et al., 2008) [9].
 290

288

291

3.4. RELATIONSHIP BETWEEN Ct VALUES AND DINAMICS OF VIRAL

293 INFECTION

294 The overall median Ct value was 29.4 (7.8), 27.6 (8.0) for the first week of symptom onset and 30.5 (7.3) for the second week. The overall median Ct values 295 296 obtained by RT-qPCR from all positive samples by RT-LAMP was 28.4 (7.0), 27.4 (7.4) in the first week, and 29.9 (6.7) in the second. A non-linear trend was found for 297 298 higher Ct values as there was a longer time of symptom onset. A direct relation of 32.6% was identified between the Ct values of the positive cases detected by RT-299 300 qPCR with the time of symptom onset (p = 0.001). Meanwhile, for the positive cases 301 according to RT-LAMP, the correlation between Ct values and time of symptom onset 302 was 35.0% (p = 0.001) (figure 3, table 9). 303

Figure 3: Distribution of Ct values obtained by RT-qPCR (reference test) using positivity data obtained in the both methods, RT-qPCR and RT-LAMP. The results indicated that the Ct values increase with the course of the disease, suggesting a decrease of viral load.

	0	verall	First week	of symptoms	Second wee	k of symptoms	Rho†	P-Value
	Positive	Median (RIQ)	Positive	Median (RIQ)	Positive	Median (RIQ)		
RT-qPCR	143	29.4 (7.8)	76	27.6 (8.0)	67	30.5 (7.3)	0.326	0.001
RT-LAMP	126	28.4 (6.9)	70	27.4 (7.4)	56	29.9 (6.7)	0.350	0.001

308 **Table 10**. Correlation between Ct values and time of illness onset.

309 †Spearman's Correlation Coefficient.

310 4. DISCUSSION

In Peru, the first measure adopted to contain the virus dissemination was the 311 guarantine that endured between March 16th and June 30th. On this long and difficult 312 time, many diagnostic strategies were implemented and until now, almost 300,000 313 samples have been processed by RT-gPCR only in the COVID-19 Emergency 314 315 Laboratory from Instituto Nacional de Salud [10]. Even though other molecular 316 biology laboratories have been implemented in different regions of the country, this strategy have not been enough to contain the virus dissemination in our country. 317 318 Peru is the sixth country of the world in total number of COVID-19 positive cases and 319 the first in the mortality (96 deceased for every 100,000 inhabitants) [11].

320 On the other hand, the sample transport logistics between collection point 321 and processing remains as a problem to overcome. In this sense, the molecular test 322 available at the healthcare unit should be a good strategy to detect on time and 323 control the SARS-CoV-2 transmissibility. To select the best diagnostic strategy, some challenges must be considered. Additionally, It is essential to have clarity about the 324 325 purpose, regulatory approval, diagnostic accuracy under ideal conditions, data on the diagnostic accuracy in clinical practice and finally, the test's performance used in 326 routine use publicly available [12]. So, the method chosen must no require complex 327 equipment or specialized human resources, must be fast producing results in short 328 329 time and must be comparable to RT-qPCR, the gold standard molecular method 330 recommended by WHO. Considering all these points, the RT-LAMP can be a feasible 331 alternative for all these requirements.

Considering the geographic and economic structure of Peru that implies directly in the logistic transport and epidemiological conditions of several infectious diseases, the Ministry of Health and INS have gradually produced and implemented

molecular diagnostic tests based on RT-LAMP method for cholera, febrile disease caused by arboviruses Zika, and Dengue. Since other researchers, during this pandemic, already described several RT-LAMP for SARS-CoV detection [7, 8, 13, 14, 15, 16, 17, 18 and 19], the INS Peruvian researchers' team selected the protocol described Lamb et al (2020) to compare its performance diagnostic in comparison with RT-qPCR. This protocol is based in a fast-colorimetric reaction and can provide results in less than 60 minutes after RNA extraction.

We compared the diagnostic performance of this specific protocol in two 342 steps of quality verification. The first step was performed as laboratory 343 344 standardization and, the second one, as clinical validation. In these two phases, 767 345 clinical samples were processed and the results indicated that this protocol have similar diagnostic performance when compared to RT-qPCR. The limit of detection of 346 347 this method was 1,000 copies/µL (table 5 and figure 1), ten times lower than RT-348 qPCR standardized and implemented in the molecular diagnostic routine by INS. However, this difference should be associated to the target gene for the methods to 349 350 be different and to be in different ORFs. The primers for RT-LAMP were designed to align in the ORF1a region, to detect a SARS-CoV-2 nsp3 gene fragment and the 351 primers for RT-qPCR, into the ORF1b, for in RdRp gene fragment. Considering the 352 CoV replication, many subgenomic RNA are generated in different quantities and this 353 particular characteristic should be considered in the molecular test using different 354 355 target gene [20]. From these replication characteristics of Coronaviridae family, the 356 WHO has suggested that the diagnosis should be conducted using primers for 357 Nucleocapsid (N) gene or for ORF1ab genes. Even so, since the ORF1ab represents 2/3 of all genome (reference sequence NC 045512.2), it should be considered that 358 the genes located on the 5' genome has less copy during replication cycle. 359

Therefore, the *nsp3* gene may have a lower amount of RNA during replication when compared to the amount of RNA for the *RdRp* gene, which would justify the lower sensitivity of the RT-LAMP test. To overcome these difficulties, we designed new set of primers for others genome regions, especially for *RdRp*, to properly compare the diagnostic performance considering the same genomic region.

365 We also showed by in silico analysis that the set of primers used for RT-366 LAMP was really specific to detect the SARS-CoV-2 Peruvian strains and did not present cross-reaction with others HCoV in molecular test (figure 2, panels A and B). 367 We know that this point was a limitation of our study because this analysis should be 368 369 done in vitro using clinical samples. Furthermore, the INS does not have positive 370 clinical samples for other HCoV. Due to the need to quickly evaluate the performance of this diagnostic method and finally start transferring this technology to the points of 371 372 attention, the alternative of verifying the occurrence of cross reaction measured by in 373 silico analysis was the most appropriate and scientifically feasible at the moment. The perfect identity in the region of primers alignment F3 and B3 with all available 374 SARS-CoV-2 Peruvian strains (figure 2, panels C and D) also indicated specific 375 detection and almost none probability of false negative results due primers 376 specificity. 377

The robustness evaluation of this RT-LAMP protocol considered variables as primers concentration and final volume of reaction. This strategy focused the fact of the reactions will be performed by people that does not present routine contact with molecular biology techniques. Since the reactions performance was not compromised using half of primers concentrations and eighty percent of final volume of reaction, technical errors that may be made during small volume pipetting.

The RT-LAMP presented a high sensitivity and specificity in the both steps of 384 quality verification (87.4% and 98.7%, 88.1% and 98.8%, available in table 8 385 386 obtained by results presented in tables 6 and 7 in the laboratory standardization and in the clinical validation, respectively). These results were similar to those reported by 387 Hu et al. (2020) [21] (88.57% and 98.98%, respectively) and lower than described by 388 Jiang et al. (2020) [8] (91.4% and 99.5%, respectively) and Kitagawa et al. (2020) 389 390 [22] (100% and 97.6%, respectively). These differences could be associated to the Ct values used to establish positivity by RT-qPCR. Furthermore, only the positive 391 392 samples that presented Ct values > 30 disagreed with those obtained by RT-LAMP. 393 So, our results indicated 100% specificity and sensitivity because Ct > 30 exceeds 394 the minimum number of copies that represents the limit of detection of this protocol. In addition, the Kappa index about 0.9 showed a virtually perfect agreement between 395 396 these tests, indicating that this RT-LAMP protocol can be used as alternative method 397 of COVID-19 molecular diagnosis at healthcare centers.

The area under the curve of the RT-LAMP test was 93.4% for the clinical assessment. We did not find any article that has reported this aspect for the RT-LAMP. However, as it is very close to 100%, it reflects that RT-LAMP can be useful enough to identify infected patients in the active transmission phase.

It was found that the RT-LAMP test, when giving a Positive Predictive Value 97.7%, in a similar way to that reported by Jiang et al. (2020) [7], PPV: 97.7%), and much higher than mentioned by Hu et al. (2020) [21] (PPV: 91.18%), the latter evaluated 329 nasal and pharyngeal swabs from a cohort of 129 COVID-19 suspects and serial upper respiratory tract samples from asymptomatic carriers, unlike our study in which only samples of symptomatic cases. Similarly, when giving a negative result, the RT-LAMP succeeded in 93.3% of the cases in identifying a person without

SARS-CoV-2 infection, which although it is somewhat lower than that reported by
Jiang et al. (2020) [7], who found a Negative Predictive Value (NPV) of 98.1%. This
difference also could be associated to prevalence obtained in each study.

The degree of agreement or concordance in the identification of SARS-CoV-412 2 between RT-qPCR and RT-LAMP at clinical assessment was 94.8%, which 413 414 indicated that there was a great concordance degree between the tests, similar to 415 that found in other studies such as the one by Lu et al. (2020) [16], and Kitagawa et al. (2020) [22], where it was always greater than 90%. In contrast, we found 20 416 discordant results between RT-LAMP and RT-qPCR in the clinical assessment, 17 417 418 false negatives and 3 false positive; Jiang et al. (2020) [7] also found 5 discordant 419 results, 4 false negatives and 1 false positive. Kitagawa et al. (2020) [22] reported only 2 discordant, which were false positives. Hu et al. (2020) [21] also identified 4 420 discordant samples, theoretically false positives; however, these were confirmed as 421 422 SARS-CoV-2 positive through a genetic sequencing test.

When evaluating the performance of the RT-LAMP by time of symptom 423 onset, we found that the sensitivity and the Negative Predictive Value were higher in 424 the first week, and although the Positive Predictive Value and the specificity showed 425 an increase towards the second week, although this increase was not significant. We 426 did not find any article that evaluates the performance of RT-LAMP by time of 427 symptom onset, but RT-qPCR shows greater performance in the first week of 428 429 symptoms; these findings could be verified with the area under the curve, which from 430 being 95.3% in first week it is reduced to 91.3% at second week of the days onset of 431 symptoms.

432 Within the clinical limitations, it should be mentioned that the RT-LAMP test 433 was only evaluated in symptomatic cases. However, the purpose of this study was to

evaluate a simple, sensitive, specific and robust, low-cost diagnostic method to beimplemented in healthcare units.

Finally, our data allow us to conclude that the RT-LAMP protocol implemented by INS should be the convenient alternative for SARS-CoV-2 detection directly at the healthcare centers in this moment. This strategy can provide appropriate prevention and control measures in all provinces and for decreasing the number of severe and non-severe cases of COVID-19.

441

442 **5. ACKNOWLEGMENTS**

443 We thank Pan American Health Organization (PAHO) for providing us the 444 reagents and to stablish collaboration to conduct the experiment validations. Our recognition to all the workers of Laboratorio de Microbiologia y Biomedicina of INS 445 and all people from others institutions involved in obtaining, handling and processing 446 447 the samples, in special to Jairo Mendez (PAHO), Rapid Response Team (CDC/INS), Lely Solari, Faviola Valdivia, Helen Horna, Gabriel de Lucio, Yanina Zarate, Iris 448 Pompa, Isidro Antipupa, Jhon Mayo, Carina Mantari, Kathia Targui, Romeo Pomari, 449 Eduardo Juscamayta, Paquita García, Miryam Palomino, Pamela Rios, Priscila Lope, 450 Johana Balbuena, Victor Jiménez, Yolanda Angulo, Yuli Barrios, Paul Pachas, 451 Noemi Flores, and Ana Zeppilli. 452

- 453
- 454

6. CONFLICT OF INTEREST

The authors declare none conflict of interest.

456

457

459 **7. REFERENCES**

- 1. who.int [Internet]. Coronavirus disease (COVID-19) pandemic. [cited 2020 Sep
- 461 24]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-
- 462 <u>2019</u>.
- 463 2. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al.
- Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;
- 465 581(7809):465-9. <u>https://doi.org/10.1038/s41586-020-2196-x</u>.
- 466 3. Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al.
- 467 Antibody tests for identification of current and past infection with SARS-CoV-2.
- 468 Cochrane Database of Systematic Reviews 2020.
- 469 <u>https://doi.org/10.1002/14651858.CD013652</u>.
- 470 4. Notomi T, Okayama H, Masubuchi H, Yonekawa T, Watanabe K et al. Loop-
- 471 mediated isothermal amplification of DNA. Nucleic Acids Res. 2000. Jun
- 472 15;28(12):E63. <u>https://doi.org/10.1093/nar/28.12.e63</u>. pmid: 10871386; pmcid:
- 473 PMC102748.
- 5. gisaid.org [Internet]. Genomic epidemiology of hCoV-19. [cited 2020 Sep 24].
- 475 Available from: <u>https://www.gisaid.org/</u>.
- 476 6. Cochran WG. Técnicas de muestreo, CECSA, México, 1985.

477 7. Jiang M, Pan W, Arasthfer A, Fang W, Ling L et al. Development and Validation of
478 a Rapid, Single-Step Reverse Transcriptase Loop-Mediated Isothermal Amplification
479 (RT-LAMP) System Potentially to Be Used for Reliable and High-Throughput

- 480 Screening of COVID-19. Front Cell Infect Microbiol 2020. 10:331.
- 481 https://doi.org/10.3389/fcimb.2020.00331.
- 482 8. Lamb LE, Bartolone SN, Ward E, Chancellor MB. Rapid Detection of Novel 483 Coronavirus (COVID-19) by Reverse Transcription-Loop-Mediated Isothermal

- 484 Amplification. PLoS One. 2020 Jun 12; 15(6):e0234682.
- 485 <u>https://doi.org/10.1371/journal.pone.0234682</u>. eCollection 2020.pmid: 32530929.
- 486 9. Parikh R, Mathai A, Parikh S, Chandra Sekhar G, Thomas R. Understanding and
- using sensitivity, specificity and predictive values. Indian J Ophthalmol. 2008. Jan-
- 488 Feb; 56(1):45-50. <u>https://doi.org/10.4103/0301-4738.37595</u>. pmid: 18158403; pmcid:
- 489 PMC2636062.
- 490 10. covid19.minsa.gob.pe. [Internet]. Sala Situacional COVID-19 Perú. [cited 2020
- 491 Sep 24]. Available from: <u>https://covid19.minsa.gob.pe/</u>.
- 492 11. coronavirus.jhu.edu/map.html. [Internet]. Coronavirus Resource Center. [cited
 493 2020 Sep 24]. <u>https://coronavirus.jhu.edu/map.html</u>.
- 494 12. who.int. [Internet]. Kosack CS, Page AL, Klatser PR. A guide to aid the
 495 selection of diagnostic tests. 2017. [cited 2020 Sep 24]. Available from:
 496 <u>https://www.who.int/bulletin/volumes/95/9/16-187468/en/</u>.
- 497 13. Ben-Assa N, Naddaf R, Gefen T, Capucha T, Hajjo H, et al. Direct on-the-spot 498 detection of SARS-CoV-2 in patients. Exp Biol Med (Maywood). 2020. Jul
- 499 16:1535370220941819. https://doi.org/10.1177/1535370220941819. Epub ahead of
- 500 print. pmid: 32668983; pmcid: PMC7385438.
- 14. Huang WE, Lim B, Hsu C-C, Xiong D, Wu W, et al. RT-LAMP for rapid
 diagnosis of coronavirus SARS-CoV-2. Microb Biotechnol. 2020.
 https://doi.org/10.1111/1751-7915.13586.
- 504 15. Kashira J, Yaqinuddina A. Loop mediated isothermal amplification (LAMP)
- assays as a rapid diagnostic for COVID-19. Medical Hypotheses, 2020, Volume 141,
- 506 August, 109786. <u>https://doi.org/10.1016/j.mehy.2020.109786</u>.

Lu R, Wu X, Wan Z, Li Y, Jin X, Zhang C. A Novel Reverse Transcription 16. 507 Loop-Mediated Isothermal Amplification Method for Rapid Detection of SARS-CoV-2. 508 509 Int. J. Mol. Sci. 2020, 21(8), 2826; https://doi.org/10.3390/ijms21082826. Osterdahl MF, Lee KA, Lochlainn MN, Wilson S, Douthwaite S, et al. Detecting 17. 510 SARS-CoV-2 at Point of Care: Preliminary Data Comparing Loop-Mediated 511 Isothermal Amplification PCR. SSRN: 512 (LAMP) to Available at 513 https://ssrn.com/abstract=3564906 or http://dx.doi.org/10.2139/ssrn.3564906. 18. Yan C, Cui J, Huang L, Du B, Chen L, Xue G, Li S, Zhang W, Zhao L, Sun Y, 514 Yao H, Li N, Zhao H, Feng Y, Liu S, et al. Rapid and visual detection of 2019 novel 515 516 coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal 517 amplification assay. Clin Microbiol Infect. 2020. Jun;26(6):773-779. https://doi.org.10.1016/j.cmi.2020.04.001. Epub 2020 Apr 8. pmid: 32276116; pmcid: 518

519 PMC7144850.

Yu L, Wu S, Hao X, Dong X, Mao L, et al. Rapid Detection of COVID-19
Coronavirus Using a Reverse Transcriptional Loop-Mediated Isothermal Amplification

522 (RT-LAMP) Diagnostic Platform. Clin Chem. 2020. Jul 1; 66(7):975-977.

523 <u>https://doi.org/10.1093/clinchem/hvaa102</u>. pmid: 32315390; pmcid: PMC7188121.

20. Case JB, Bailey AL, Kim AS, Chen RE, Diamond MS. Growth, detection, quantification, and inactivation of SARS-CoV-2. Virology 2020. https://doi.org/10.1016/j.virol.2020.05.015.

Hu X, Deng Q, Li J, Chen J, Wang Z, Zhang X, et al. Development and Clinical
Application of a Rapid and Sensitive Loop-Mediated Isothermal Amplification Test for
SARS-CoV-2 Infection. Spiropoulou CF, editor. mSphere. 2020; 5(4):e00808-20,
/msphere/5/4/mSphere808-20.atom. https://doi.org/10.1128/mSphere.00808-20.

- 531 22. Kitagawa Y, Orihara Y, Kawamura R, Imai K, Sakai J, Tarumoto N, et al.
- 532 Evaluation of rapid diagnosis of novel coronavirus disease (COVID-19) using loop-
- mediated isothermal amplification. Journal of Clinical Virology. 2020; 129:104446.
- 534 <u>https://doi.org/10.1016/j.jcv.2020.104446</u>.



Data Display Search Groups Highlight Statistics Help	_	-	_								_														
□												F3													
✓ Name	-	•	- 1	-		C	C	A	G A	T	G	A	G	G A	T	G	A	A G	A	A	G A	-		-] [-	-
✓ 1. Primer F3	-		· .	-						Č. (*												-			
✓ 2. NC 045512.2 Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1 complete genome	C	С	¢.	-																		A	G	5 T	
☑ 3. NC 004718.3 SARS coronavirus Tor2 complete genome	C	С	È .	-											A					G		С	G A	A T	(
✓ 4. NC 019843.3 Middle East respiratory syndrome coronavirus complete genome	C	т	T G	; -			т	T	C T	٢.	C	т	A	. т	C	т	т				c -	-			
✓ 5. FJ415324.1 Human enteric coronavirus 4408 complete genome	A	G	Б.	-		G	т		. 0	5.		с	Τ.	Α.	A		T	TA	G	т	. 0	С			
	A	G	б.	-		G	т		. 0	÷ .		с	Т	Α.	A		Т	TA	G	т	. 0	С			
☑ 7. NC 005831.2 Human Coronavirus NL63 complete genome	т	G	τ.	G	A	۷.		т	AC	c	c	2	Т	Α.	A		T	C A		G	CT	С	AT	Γ A	. 1
☑ 8. NC 006577.2 Human coronavirus HKU1 complete genome	A	G	Α.	-		G	т	т	. 1	Γ.	A	С	т	. G			. (CA	۰.	т		С	G A	A T	(
	С	A	τ.	G	A	١.		т	. 1	Γ.	т		C	A G	A		T	CA	١.	G	CI	т	TC	S C	1

Α

Data Display Search Groups Highlight Statistics Help									_	_	_	_	_	_	_			_	_					_			
🖬 🚓 🕼 🌆 💔 🏋 C V Pi S 0 2 4 🌟 - 🤮 🤗	B3						B3																				
✓Name			1-		•	-			C	T	ΤA	C	A	C C	A	G	TT	G	TI	r c	A	G /	A C	Т		-	-
I. Primers B3 RC			-																								
2. NC 045512.2 Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1 complete genome	1 0	G A	G	G A	Т	G	G	A A																	A T	Т	G
✓ 3. NC 004718.3 SARS coronavirus Tor2 complete genome	1 0	G A	A	AC	c	A	G	AA		C					т		AA				-	A		С	Α -	-	
✓4. NC 019843.3 Middle East respiratory syndrome coronavirus complete genome	A T	тт	G	G A	C	G	C	A C		A	G		T	A T	т		с.	т	. A	AA	C	. (ст	G	Α.	-	
✓ 5. FJ415324.1 Human enteric coronavirus 4408 complete genome	5 A	A -	-	A	C	A	G			- (σ.	G	G	A G	т	С		с	. 0	A G		A	г.		TA	G	A
✓ 6. NC 006213.1 Human coronavirus OC43 strain ATCC VR-759 complete genome	5 A	A -	-	- A	C	A	G			- (5.	G	G	A G	т	С		с	. 0	A G			Γ.		T A	G	A
✓ 7. NC 005831.2 Human Coronavirus NL63 complete genome	гт	тт	т	T G	A	A	G	AA	G		G	A		. A	т		. G	с	. 0	т	С	A	. т		Α.	-	-
✓8. NC 006577.2 Human coronavirus HKU1 complete genome	5 A	A C	A	AA	т	A	A	C G	A	. (5.	A	G	A G		т	. G	т	. A	4 .	т	. (G T	G	AC	A	A
9. NC 002645.1 Human coronavirus 229E complete genome	5 A	A C	A	A G	Т	G	G	A T	G			A		. A	Т			- 2				A	T G		G.		

MX: Alignment Explorer (Alig_SARS-CoV-2_1940	ienCompl	+F3_PERU_Edit	tado.fas)		
Data Edit Search Alignment	Web	Sequencer	Display	Help	
1 💳 🖬 📽 🖃 💵 🔠 💵 🦾	F 11.	-	* 🖪 ×	<u> </u>	
DNA Sequences Translated Protein Sequences				F3	
Species/Abbry					
1. Primer_F3				TCCAGATGAGGATGAAGAAGA	
2. NC_045512.2_Severe_acute_respiratory_syndrome_	GTAT	TGTTCT	TTCTACCO	C T C C A G A T G A G G A T G A A G A A G A A G G	TGATT
3. hCoV-19/Peru/LAL-INS-056/2020[EPI_ISL_517686]202	GTAT	TGTTCT	тттт 🗛 с с с	C T C C A G A T G A G G A T G A A G A A G A A G G	TGATT
4. hCoV-19/Peru/LAL-INS-070/2020[EPI_ISL_523810]202	GTAT	TGTTCT	<mark>ттст</mark> А с с с	C T C C A G A T G A G G A T G A A G A A G A A G G	TGATT
5. hCoV-19/Peru/LAL-INS-064/2020[EPI_ISL_525206]202	GTAT	TGTTCT	т <mark>т с т </mark> с с с	C T C C A G A T G A G G A T G A A G A A G A A G G A	TGATT
6. hCoV-19/Peru/LOR-INS-058/2020 EPI_ISL_514317 202	GTAT	TGTTCT	TTTTACCO	C T C C A G A T G A G G A T G A A G A A G A A G G	TGATT
7. hCoV-19/Peru/LOR-INS-079/2020[EPI_ISL_514339]202	GTAT	TGTTCT	гттт <mark>д</mark> сс (C T C C A G A T G A G G A T G A A G A A G A A G G	TGATT
8. hCoV-19/Peru/LOR-INS-080/2020[EPI_ISL_514340]202	GTAT	TGTTCTI	гттт <mark>д</mark> ссс	C T C C A G A T G A G G A T G A A G A A G A A G G	TGATT
9. hCoV-19/Peru/LOR-INS-081/2020[EPI_ISL_514341]202	GTAT	TGTTCTT	тттт <mark>д</mark> сс (CTCCAGATGAGGATGAAGAAGAAGA	TGATT
10. hCoV-19/Peru/LOR-INS-082/2020[EPI_ISL_514342]20	GTAT	TGTTCT	тттт 🗛 ссо	C T C C A G A T G A G G A T G A A G A A G A A G G	TGATT
11 hCoV-19/Peru/I IM-UPCH-0004/2020IFPL ISI 529066	GTAT	TGTTCT	TTTACCO	CTCCAGATGAGGATGAAGAAGAAGA	TGATT

С

MX: Alignment Explorer (Alig_SARS-CoV-2_194GenCompl+B3_PERU_Editado.fas)	
Data Edit Search Alignment Web Sequencer Display Help	
1 ➡ 🖬 📽 🗒 🗰 🚳 💯 💪 🕨 1. 🔸 🗈 🛠 15 × 3. + - 🚱 ଏ 🕨 🍳 🤤 🖕	
DNA Sequences Translated Protein Sequences	B3
Species/Abbry	
1. Primers_B3_RC	CTTACACCAGTTGTTCAGACT
2. NC_045512.2_Severe_acute_respiratory_syndrome_coronavir GAGGACAATCAGACAACTACTATTCAAACAATTGTTGAGGTTCAACCTCAATTAGAGATGGAA	C T T A C A C C A G T T G T T C A G A C T A T T I
3. hCoV-19/Peru/LAL-INS-056/2020/EPL/SL_517686/2020-04-12 GAGGACAATCAGACAACTACTATTCAAACAATTGTTGAGGTTCAACCTCAATTAGAGATGGAA	C T T A C A C C A G T T G T T C A G A C T A T T I
4. hCoV-19/Peru/LAL-NS-070/2020/EPL/SL_523810/2020-03-11 GAGGACAATCAGACAACTACTATTCAAACAATTGTTGAGGTTCAACCTCAATTAGAGATGGAA	C T T A C A C C A G T T G T T C A G A C T A T T I
5. hCoV-19/Peru/LAL-NS-064/2020/EPI_ISL_525206/2020-03-14 GAGGACAATCAGACAACTACTACTATTCAAACAATTGTTGAGGTTCAACCTCAATTAGAGATGGAA	C T T A C A C C A G T T G T T C A G A C T A T T I
6. hCoV-19/Peru/LOR-INS-058/2020/EPI_ISL_514317/2020-04-02 GAGGACAATCAGACAACTACTACTATTCAAACAATTGTTGAGGTTCAACCTCAATTAGAGATGGAA	C T T A C A C C A G T T G T T C A G A C T A T T I
7. hCoV-19/Peru/LOR-INS-079/2020/EPI_ISL_514339/2020-04-22 GAGGACAATCAGACAACTACTACTACTATTCAAACAATTGTTGAGGTTCAACCTCAATTAGAGATGGAA	C T T A C A C C A G T T G T T C A G A C T A T T I
8. hCoV-19/Peru/LOR-INS-080/2020/EPI_ISL_514340/2020-04-22 GAGGACAATCAGACAACTACTATTCAAACAATTGTTGAGGTTCAACCTCAATTAGAGATGGAA	C T T A C A C C A G T T G T T C A G A C T A T T I
9. hCoV-19/Peru/LOR-INS-081/2020/EPI_ISL_514341/2020-04-22 GAGGACAATCAGACAACTACTATTCAAACAATTGTTGAGGTTCAACCTCAATTAGAGATGGAA	C T T A C A C C A G T T G T T C A G A C T A T T I
10. hCoV-19/Peru/LOR-INS-082/2020/EPL/SL_514342/2020-04-22 GAGGACAATCAGACAACTACTACTATTCAAACAATTGTTGAGGTTCAACCTCAATTAGAGATGGAA	C TTACACCAGTTGTTCAGAC TATTI
11. hCoV-19/Peru/LIM-UPCH-0004/2020[EPLISL_529086[2020-06-GAGGACAATCAGACAACTACTATTCAAACAATTGTTGAGGTTCAACCTCAATTAGAGATGGAA	C T T A C A C C A G T T G T T C A G A C T A T T

D

